Why Revolution Medicines (RVMD) Is Up 6.2% After Early Zoldonrasib Pancreatic Cancer Data And What’s Next
In late June and early July 2026, Revolution Medicines reported Phase 1/2 data showing that its RAS G12D…
Daraxonrasib’s Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMD
Revolution Medicines recently reported detailed Phase 3 RASolute 302 data showing once-daily oral daraxonrasib delivered unprecedented overall and…